Cogent's Bezuclastinib-Sunitinib Combo Nearly Doubles Progression-Free Survival in Second-Line GIST, the First Positive Phase 3 in Two Decades
Cogent's bezuclastinib plus sunitinib reached 16.5-month median PFS versus 9.2 months in second-line GIST, with FDA Priority Review and a November 30 PDUFA date.